Roivant Sciences Ltd.
Cash Flow Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-299.8M | $-172.0M | $4.35B | $-1.01B | $-845.3M | $-809.2M |
| Depreciation & Amortization | $3.3M | $14.1M | $22.0M | $18.9M | $5.9M | — |
| Depreciation | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $346.2M | $289.0M | $199.6M | $217.8M | $565.0M | $85.0M |
| Net Cash from Operating Activities | $-750.3M | $-839.5M | $-765.3M | $-843.4M | $-677.7M | $-552.1M |
| Investing Activities | ||||||
| Capital Expenditures | $8.2M | $4.6M | $1.4M | $12.7M | $17.4M | $5.8M |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-682.3M | $-1.77B | $5.20B | $-44.3M | $303.3M | $-31.7M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | $1.29B | $0 | $0 | — | — |
| Net Cash from Financing Activities | $134.2M | $-1.22B | $419.4M | $499.5M | $306.8M | $456.3M |
| Net Change in Cash | $-1.29B | $-3.82B | $4.86B | $-381.9M | $-67.6M | — |
| Free Cash Flow | $-758.6M | $-844.1M | $-766.7M | $-856.1M | $-695.2M | $-557.9M |